NEW YORK (360Dx) – A team of investigators at the University Hospital of Wales has, in collaboration with PerkinElmer, developed an automated immunoassay that could be used to screen newborns for a biomarker linked to Duchenne muscular dystrophy.

The developers maintain that the new assay would address an unmet market need, and pilot studies are now underway in the US and China, following a successful evaluation of the test in the UK, detailed recently in the journal Clinical Chemistry.